Intellia Therapeutics Files 8-K with Bylaw Amendments
Ticker: NTLA · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1652130
Sentiment: neutral
Topics: corporate-governance, filing, exhibits
TL;DR
Intellia filed an 8-K for bylaw changes and exhibits, no major news yet.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting an event on April 3, 2025. The filing indicates amendments to its articles of incorporation or bylaws and includes financial statements and exhibits. No specific financial figures or significant operational changes were detailed in the provided excerpt.
Why It Matters
This filing signals potential changes in Intellia's corporate governance or structure, which could impact its operational framework and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- April 3, 2025 (date) — Date of Earliest Event Reported
- April 7, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
FAQ
What specific amendments were made to Intellia Therapeutics' articles of incorporation or bylaws?
The provided excerpt does not detail the specific amendments made to the articles of incorporation or bylaws; it only states that such amendments were reported.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing of 'Financial Statements and Exhibits' indicates that the company is providing updated financial information or supplementary documents as required by the SEC, though the content of these is not specified in the excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 3, 2025.
What is Intellia Therapeutics, Inc.'s principal executive office address?
Intellia Therapeutics, Inc.'s principal executive office is located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the SEC file number for Intellia Therapeutics, Inc.?
The SEC file number for Intellia Therapeutics, Inc. is 001-37766.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Intellia Therapeutics, Inc. (NTLA).